Literature DB >> 33027223

The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia.

Calvin Yeang1, Peter Willeit2,3, Sotirios Tsimikas1.   

Abstract

PURPOSE OF REVIEW: Elevated levels of lipoprotein(a) [Lp(a)] are present in 30-50% of patients with familial hypercholesterolemia. The contribution of Lp(a) towards risk stratification of patients with familial hypercholesterolemia has been recently recognized, with studies showing a significantly worse prognosis if Lp(a) is elevated. However, the role of elevated Lp(a) in diagnosis of familial hypercholesterolemia is less well defined or accepted. RECENT
FINDINGS: An important confounder in the diagnosis of familial hypercholesterolemia is the significant contribution of the cholesterol content on Lp(a) (Lp(a)-C) in individuals with elevated Lp(a). Because Lp(a)-C is incorporated into all clinical LDL-C measurements, it can contribute significantly to the cholesterol threshold diagnostic criteria for familial hypercholesterolemia used in most clinical algorithms.
SUMMARY: In this review, we discuss the interrelationship of Lp(a), Lp(a)-C and correct LDL-C in the diagnosis and prognosis of familial hypercholesterolemia. Future studies of accurately measuring correct LDL-C or in using apoB-100 and Lp(a) criteria may overcome the limitations of using estimated LDL-C in the diagnosis of familial hypercholesterolemia in individuals with concomitant elevation of Lp(a).

Entities:  

Year:  2020        PMID: 33027223     DOI: 10.1097/MOL.0000000000000713

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  2 in total

1.  Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia.

Authors:  Brian Tomlinson; Nivritti Gajanan Patil; Manson Fok; Christopher Wai Kei Lam
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-19

2.  Improving Familial Hypercholesterolemia Diagnosis Using an EMR-based Hybrid Diagnostic Model.

Authors:  Wael E Eid; Emma Hatfield Sapp; Abby Wendt; Amity Lumpp; Carl Miller
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.